IGHA1 and hepatocellular carcinoma: The non-glycosylated peptides from IgA1 (amino acids 332–353; termed as IgA1[332–353]) did not show significant differences in the progression of HBV-HCC, while IgA1[127–153] and IgG2[172–180] were only detected in HBV-HCC (Fig. 8D), suggesting that fucosylated peptides from IgA1 and IgG2, especially IgA1[332–353], were specially up-regulated in the progression of HBV-HCC.